Related references
Note: Only part of the references are listed.Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response
Mayra Yebra et al.
CLINICAL CANCER RESEARCH (2022)
Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors
Ji Hyun Lee et al.
CANCERS (2022)
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2021)
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Robin L. Jones et al.
EUROPEAN JOURNAL OF CANCER (2021)
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
John R. Zalcberg et al.
ONCOLOGIST (2021)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial
Michael C Heinrich et al.
LANCET ONCOLOGY (2020)
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D. Smith et al.
CANCER CELL (2019)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib
Scott M. Schuetze et al.
JAMA ONCOLOGY (2018)
A Novel PRKAR1B-BRAF Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy
Lindsey M. Charo et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis
J. Martin-Broto et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
The Call of The Wild-Type GIST: It's Time for Domestication
Maha Alkhuziem et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors A single-institutional experience in China
Weizhen Liu et al.
MEDICINE (2017)
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib An Exploratory Analysis of a Randomized Clinical Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2017)
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results Analysis of Phase 3 SWOG Intergroup Trial S0033
Michael C. Heinrich et al.
JAMA ONCOLOGY (2017)
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
E. Ben-Ami et al.
ANNALS OF ONCOLOGY (2016)
Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group
Anna Patrikidou et al.
EUROPEAN JOURNAL OF CANCER (2016)
Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST
Monica Brenca et al.
JOURNAL OF PATHOLOGY (2016)
FGFR1 and NTRK3 actionable alterations in Wild-Type gastrointestinal stromal tumors
Eileen Shi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial
Olivier Mir et al.
LANCET ONCOLOGY (2016)
Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic
Sosipatros A. Boikos et al.
JAMA ONCOLOGY (2016)
Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case
Martin G. Belinsky et al.
BMC CANCER (2015)
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2015)
Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study
Grace L. Ma et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2015)
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib
K. N. Ganjoo et al.
ANNALS OF ONCOLOGY (2014)
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis
M. Montemurro et al.
EUROPEAN JOURNAL OF CANCER (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience
Umut Kefeli et al.
ONCOLOGY LETTERS (2013)
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib
P. Reichardt et al.
ANNALS OF ONCOLOGY (2012)
Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
C. Cauchi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Philippe A. Cassier et al.
CLINICAL CANCER RESEARCH (2012)
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group
S. H. Park et al.
INVESTIGATIONAL NEW DRUGS (2012)
Succinate Dehydrogenase-Deficient GISTs: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 66 Gastric GISTs With Predilection to Young Age
Markku Miettinen et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Phase 2 Study of Nilotinib as Third-Line Therapy for Patients With Gastrointestinal Stromal Tumor
Akira Sawaki et al.
CANCER (2011)
A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).
J. C. Trent et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.
H. L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations
Katherine A. Janeway et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
P. Schoffski et al.
ANNALS OF ONCOLOGY (2010)
Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance
Tianhua Guo et al.
CLINICAL CANCER RESEARCH (2009)
A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib
M. Montemurro et al.
EUROPEAN JOURNAL OF CANCER (2009)
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
S. George et al.
EUROPEAN JOURNAL OF CANCER (2009)
Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene
Toshirou Nishida et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients
Ketan S. Gajiwala et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation
Barbara Dewaele et al.
CLINICAL CANCER RESEARCH (2008)
Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials
Shreyaskumar Patel et al.
EUROPEAN JOURNAL OF CANCER (2008)
Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
Narasimhan P. Agaram et al.
GENES CHROMOSOMES & CANCER (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
Jayesh Desai et al.
CLINICAL CANCER RESEARCH (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gastrointestinal stromal tumors: Pathology and prognosis at different sites
Markku Miettinen et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2006)
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours
Maria Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2006)
Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors
EA Perez et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2006)
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
E Wardelmann et al.
CLINICAL CANCER RESEARCH (2006)
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients
O Maertens et al.
HUMAN MOLECULAR GENETICS (2006)
PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
JR Zalcberg et al.
EUROPEAN JOURNAL OF CANCER (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1,458 cases from 1992 to 2000
T Tran et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter et al.
EUROPEAN JOURNAL OF CANCER (2004)
Biology of gastrointestinal stromal tumors
CL Corless et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors
S Hirota et al.
GASTROENTEROLOGY (2003)
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
RP DeMatteo et al.
HUMAN PATHOLOGY (2002)
Share Paper
